Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 79

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 79
---
----|:-----|:-------|:----|:-----|:------|:----|:-------|-----:|:--|
| Mounjaro – Worldwide |     | $    | 11.54B |     | $    | 5.2B  |     |        |  124 | % |
| Zepbound – U.S.      |     | $    | 4.9B   |     | $    | 176M  |     |        | 2684 | % |
| Rybelsus DKK M       |     | $    | 29.1B  |     | $    | 26.4B |     |        | 10.2 | % |
| Ozempic DKK M        |     | $    | 12.2B  |     | $    | 7.4B  |     |        |   65 | % |
| Wegovy DKK M         |     | $    | 11.4B  |     | $    | 1.9B  |     |        |  500 | % |

| 40 |

Figure:Estimates of the Weight Loss Target Population.

| 41 |

License Agreement with MIRALOGX

On March 26, 2025, SKNY entered into an exclusive licensing agreement with MIRALOGIX LLC, a Florida limited liability company, for the licensing by MIRALOGX to SKNY the commercial rights of SKNY-1, or M308 in the United States, Mexico and Canada (the “SKNY-1 Licensing Agreement”). Under the SKNY-1 Licensing Agreement, beginning in the calendar year during which revenue is first received by SKNY for SKNY-1, SKNY-1 will pay MIRALOGX a minimum annual royalty of two hundred fifty thousand dollars ($250,000). In the event the earned royalty in any calendar year exceeds the minimum royalty payment due for that calendar year, the excess amount shall be credited to any deficiency in the minimum annual royalty payment due in subsequent years. Payment of unearned royalty in any given year shall be credited to earned royalty in any subsequent year. Additionally, SKNY also agrees to pay MIRALOGX an amount equal to eight percent (8.0%) of the consideration actually received by SKNY for the invoice price for SKNY-1 (the “Net Sales Price”) and total revenue (less the